Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects

Molecules. 2021 Jun 29;26(13):3966. doi: 10.3390/molecules26133966.

Abstract

Inert microspheres, labeled with several radionuclides, have been developed during the last two decades for the intra-arterial treatment of liver tumors, generally called Selective Intrahepatic radiotherapy (SIRT). The aim is to embolize microspheres into the hepatic capillaries, accessible through the hepatic artery, to deliver high levels of local radiation to primary (such as hepatocarcinoma, HCC) or secondary (metastases from several primary cancers, e.g., colorectal, melanoma, neuro-endocrine tumors) liver tumors. Several types of microspheres were designed as medical devices, using different vehicles (glass, resin, poly-lactic acid) and labeled with different radionuclides, 90Y and 166Ho. The relationship between the microspheres' properties and the internal dosimetry parameters have been well studied over the last decade. This includes data derived from the clinics, but also computational data with various millimetric dosimetry and radiobiology models. The main purpose of this paper is to define the characteristics of these radiolabeled microspheres and explain their association with the microsphere distribution in the tissues and with the clinical efficacy and toxicity. This review focuses on avenues to follow in the future to optimize such particle therapy and benefit to patients.

Keywords: dosimetry; liver radioembolization; radiolabeled microspheres.

Publication types

  • Review

MeSH terms

  • Embolization, Therapeutic*
  • Holmium / therapeutic use*
  • Humans
  • Microspheres*
  • Neoplasms / therapy*
  • Radiopharmaceuticals / therapeutic use*
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Holmium